Abstract
Addition of clinically-relevant levels of 3′-Azido-3′-deoxythymidine (AZT) to cultured HepG2 cells increases the number of reactive radical species (reactive oxygen and nitrogen species [ROS and RNS]) as well as random mutations in mitochondrial DNA (mtDNA). Co-treatment of AZT-exposed cells with palm fruit juice (PFJ) mitigates AZT mutagenesis. These findings suggest that AZT-dependent mtDNA damage resulted from increased reactive species and that PFJ, a known anti-oxidant, mitigated such damage by decreasing the levels of these species. The present report tests the predictions that (1) PFJ mitigates AZT mutagenesis by reducing the burden of AZT-induced reactive species, and (2) AZT-induced mutations in mtDNA should predominantly consist of G → T and C → A substitutions characteristic of DNA oxidative damage. Levels of reactive species and mitochondrial mutagenesis were measured in HepG2 cells exposed AZT in the presence or absence of PFJ. Controls experiments showed that PFJ in HepG2 cells exhibited strong scavenging activity against hydrogen peroxide-induced ROS, the main reactive species generated by dysfunctional mitochondria. Despite this strong antioxidant activity PFJ did not decrease AZT-induced reactive species at a concentration that mitigated mtDNA mutations. Consistent with this observation, the spectrum of AZT-induced mutations did not fit the spectrum expected from direct mtDNA oxidative damage. Instead, the spectrum obtained was consistent with the majority of mutations (80%) arising from mitochondrial DNA polymerase errors induced by AZT. These observations suggest that oxidative damage was not the major contributor to AZT-induced mutations.
Highlights
The nucleotide reverse transcriptase inhibitor 3′-Azido-3′deoxythymidine (AZT, zidovudine) is a key drug used to treat HIV/ AIDS in many countries of the developing world
HepG2 cells were treated with H2O2 to test the anti-oxidant activity of PJF in our system since H2O2 is the major source of ROS in dysfunctional mitochondria [22]
A major conclusion from this work is that oxidative stress caused by AZT treatment is only a minor contributor to mitochondrial DNA (mtDNA) mutations
Summary
The nucleotide reverse transcriptase inhibitor 3′-Azido-3′deoxythymidine (AZT, zidovudine) is a key drug used to treat HIV/ AIDS in many countries of the developing world. AZT treatment, causes both short and long term toxic side effects (skeletal and cardiac myopathies, hyperlactatemia, peripheral neuropathy, increased incidence of diabetes and neurological disorders). These pathologies are consistent with AZT treatment leading to mitochondrial dysfunction and increased oxidative stress [1,2,3]. AZT may cause mitochondrial mutations and dysfunction by increasing the levels of reactive species (reactive oxygen and nitrogen species [ROS and RNS]) within mitochondria [5,6,7,8,9] These reactive species oxidize DNA leading to the formation of 8-oxo-7,8-dihydro-2'deoxyguanosine (8-oxo-dG), 8-nitro-7,8-dihydro-2'-deoxyguanosine (8-nitro-dG), and other less frequent oxidation products. Mis-pairing of 8-oxo-dG and 8-nitro-dG results in G → T and C → A nucleotide substitutions characteristic of oxidative damage [10,11,12,13,14]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.